OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Higano on Radium-223 for Prostate Cancer

June 27th 2017

Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer

June 27th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Machiels on Challenges and Ongoing Trials in Head and Neck Cancer

June 27th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.

Dr. Pinato Discusses Intra-tumor Heterogeneity in Primary and Metastatic HCC

June 26th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in primary and metastatic hepatocellular carcinoma (HCC).

Dr. Cheng on Phase III Findings of Lenvatinib in HCC

June 26th 2017

Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Uses of MRI Testing in Prostate Cancer

June 23rd 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses some potential uses of MRI testing for patients with prostate cancer.

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

June 23rd 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Dr. Lara on Epacadostat Plus Pembrolizumab in RCC

June 23rd 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Dr. Ferris on the Safety Profile for RTOG 3504 for Head and Neck Cancer

June 23rd 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer.

Dr. Stephenson on the Impact of Active Surveillance in Prostate Cancer

June 23rd 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

June 23rd 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Dr. Komrokji Discusses Molecular Testing for MDS

June 23rd 2017

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses molecular testing for patients with myelodysplastic syndromes (MDS).

Dr. Wilky on Determining Treatments for Sarcoma

June 23rd 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses how to determine which treatment a patient with sarcoma should receive.

Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

June 23rd 2017

Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

June 23rd 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

June 23rd 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Dr. Machiels on Pembrolizumab in Head and Neck Cancer

June 23rd 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

June 23rd 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

June 22nd 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.